Predictors of efficacy, mucosal healing and dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary
L Kiss, P Miheller, T Molnár, L Lakatos, Á Vincze, K Palatka, B Gosztonyi, Á Salamon, G Horváth, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, P Lakatos · Zeitschrift für Gastroenterologie · 2011 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background/Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease (CD) in clinical trials. In the present study our aim was to investigate the accuracy of clinical and laboratory markers for the prediction of medium term efficacy and mucosal healing during adalimumab therapy in patients with CD in specialized centers approved for biological therapy in Hungary. Methods: Data of 200 CD patients were analyzed (male/female: 111/89, median age: 33.0 years, duration: 8 years). Indication for biologic therapy was active luminal dise…
